Health and wellness is the only category where plans to increase spending outweigh plans to cut back in 2026, according to December 2025 data from CivicScience. That’s why retailers are stepping up their investments in wellness-driven products, services, and in-store experiences, trying to capitalize on consumers’ resolutions well into the new year.
Clinicians and staff adopt “shadow AI” tools to move faster, exposing gaps in hospital AI strategy.
Wisp acquires TBD Health to scale nationwide, adding clinics and diagnostics to meet rising demand for virtual care among women.
The healthcare giant’s forecasted decline in revenues signals an industry-wide pivot from expansion to cost discipline.
Roche’s obesity drug results show up to 22.5% weight loss, hinting at future competition for Novo and Lilly.
Major regulatory upheaval affecting pharma’s core business is unlikely to materialize this year.
Heavy consumer AI health use raises pressure on OpenAI and peers to tighten safeguards fast.
Lilly’s tirzepatide is projected to top 2026 sales as pills and uses beyond diabetes and weight loss expand demand.
51% US consumers now notice healthcare and pharma advertising on CTV, putting it ahead of search and social.
Young people overwhelmingly confide in chatbots even as questions around safety and mental health risks mount.
UnitedHealth will issue ACA refunds, but the move mirrors industry pledges—headline-friendly and light on accountability.
Amazon bets on AI health guidance paired with doctor access—something ChatGPT and Claude don’t offer.
Prescription drug advertising approached $6 billion in 2025, led by weight loss, mental health, and cancer medications.
Our analysts (or “bakers”) compete in a Great British Bake Off–style episode, discussing why Dr. Google will give way to Dr. ChatGPT in 2026 and how Americans will increasingly use AI for mental health therapy and support this year. Join Senior Director of Podcasts and host Marcus Johnson, along with Senior Analysts Rajiv Leventhal and Beth Snyder Bulik. Listen everywhere, and watch on YouTube and Spotify.
The first year of Trump’s second term has brought disruption and uncertainty, reshaping retail, media advertising, tech, health, and financial services.
More than a third of patients will switch doctors who don’t modernize the experience.
The biggest women’s health opportunity may actually be in common diseases that affect women differently and go ignored.
Rigorous data gives acetaminophen brands footing to reassure pregnant consumers.
The riff on Apple’s Mac versus PC campaign lightens the pharma tone while also leaning more into disclosures.
Novo and Lilly prohibit telehealth partners from offering compounded GLP-1s, eroding compounders’ ability to distribute.